Beijing Tri-Prime Gene Pharmaceutical Co, Ltd. (referred to as Tri-Prime Gene, stock code: 837344) is a modern pharmaceutical biotechnology enterprise with a registered capital of 121.81 million RMB. It is mainly engaged in the research, development, production, and sales of pharmaceutical biotechnology products, including gene engineering drugs, gene engineering vaccines, and diagnostic reagents. It also engages in related technical trade and technical consulting services.

Tri-Prime Gene was established in 1992 and is the first company in China named after gene engineering proprietary technology. Its co-founders are Mr. Hou Yunda - former Vice President of the Chinese Academy of Engineering and Mr. Cheng Yongqing - one of the earliest professional manager in high-tech entrepreneurship and venture capital in China.

Tri-Prime Gene's main product, recombinant human gene engineering α1b interferon, is China's first gene engineering class I new drug with independent intellectual property rights. It is used for the treatment of various viral diseases and malignant tumors; Hapgen® (human interferon α1b) has established a high-quality brand for Chinese gene engineering drugs, creating good economic and social benefits.

Tri-Prime Gene has strong R&D capabilities. In 2001, the Tri-Prime Gene R&D Center was approved by the Ministry of Personnel to establish a post-doctoral research station, possessing multiple clinical research new drug projects with international advanced levels, and more than fifty invention patents in China, the United States, and other countries. Tri-Prime Gene has undertaken more than twenty national and Beijing municipal key science and technology plan projects, obtaining more than ten new drug certificates and production approval documents.